COPD Respiratory Antimuscarinics Drug Class Monograph
|
|
- Amberly Peters
- 6 years ago
- Views:
Transcription
1 Line of Business: Medi-Cal Effective Date: May 17, 2017 Revision Date: May 17, 2017 COPD Respiratory Antimuscarinics Drug Class Monograph This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic Subcommittee. Drugs: Anoro Ellipta (umeclidinium/vilanterol), Bevespi Aerosphere (glycopyrronium/formeterol), Incruse Ellipta (umeclidinium bromide), Spiriva HandiHaler (tiotropium), Spiriva Respimat (tiotropium), Stiolto Respimat (olodaterol/tiotropium), Tudorza Pressair (aclidinium), Utibron Neohaler (indacaterol/glycopyrrolate) Policy/Criteria: A. Non-formulary COPD long acting muscarinic agonist inhaler Diagnosis: a. COPD Specialist: Not Applicable Criteria: a. Failure or clinically significant adverse effects to ONE formulary long acting bronchodilator: Incruse Ellipta, Stiolto Respimat, Tudorza or Serevent. B. Non-formulary COPD long acting combination muscarinic agonist and beta agonist inhaler Diagnosis: a. COPD Specialist: Not Applicable Criteria: a. Failure or clinically significant adverse effects to Stiolto Respimat
2 Clinical Justification: 2017 Global Initiative for Chronic Obstructive Lung Disease Bronchodilators in Stable COPD: Bronchodilator medications are central to symptom management in COPD Inhaled therapy is preferred. The choice between beta-agonist, anticholinergic, theophylline or combination therapy depends on availability and individual patient response in terms of symptom relief and side effects Bronchodilators are prescribed on as-needed or on a regular basis to prevent or reduce symptoms Long-acting inhaled bronchodilators are convenient and more effective at producing maintained symptom relief than short-acting bronchodilators Combining bronchodilators of different pharmacological classes may improve efficacy and decrease the risk of side effects compared to increasing the dose of a single bronchodilator Anticholinergics: Tiotropium reduces exacerbations and related hospitalizations, improves symptoms and health status (Evidence A), and improve the effectiveness of pulmonary rehabilitation (Evidence B). The long acting anticholinergics aclidinium and glycopyrronium seem to have similar action on lung function and breathlessness as tiotropium, whereas far less data are available for other outcomes. Combination Bronchodilator Therapy: Combinations of a long-acting beta2 agonist and a long-acting anticholinergic are superior compared to either medication alone in improving FEV1 and symptoms (Evidence A). Combinations of a long-acting beta2 agonist and a long-acting anticholinergic reduce exacerbations compared to monotherapy (Evidence B) or inhaled corticosteroids and long-acting beta2 agonists (Evidence B). The combined use of short or long-acting beta2-agonists and anticholinergics may be considered if symptoms are not improved with single agents. (Evidence B) Comparing tiotropium with other long-acting anticholinergics: In a small trial, a randomized, double-blind, and crossover clinical study comparing aclidinium 400mcg twice daily with tiotropium 18mcg once daily in moderate to severe COPD patients, improvements in FEV1 were superior than placebo, but not significantly different from each other.
3 In a 12-week, randomized, double-blinded clinical study, glycopyrronium 50 mcg demonstrated non-inferiority to tiotropium 18 mcg in trough FEV1 at week 12 and indicated similar effect of both treatments on lung function and clinical outcomes in patients with moderate-to-severe COPD.
4 Monotherapy Anticholinergic Bronchodilator Drugs Atrovent HFA (ipratropium) Spiriva HandiHaler (tiotropium) Spiriva Respimat (tiotropium) MOA Short-acting anticholinergic agent that blocks acetylcholine at parasympathetic site in bronchial smooth muscle causing bronchodilation Long-acting anticholinergic agent that competitively and reversibly inhibits acetylcholine at M3 receptors in bronchial smooth muscle causing bronchodilation; affinity for muscarinic subtypes M1 through M5 Usual Dosing 2 inhalations four 2 inhalations of one 2 inhalations once daily times daily, not to exceed 12 inhalations in 24 hours capsule once daily FDA Indication COPD COPD COPD Asthma, maintenance therapy Pediatric Indication Not approved for children under 12 years of age Not indicated for use in children; efficacy and safety not established Asthma, maintenance therapy for 6 years and older Administration Use HFA canister with provided mouthpiece; wash mouthpiece with warm water only at least once a week for 30 seconds and air-dry completely. Prime HFA canister against mouthpiece 2 times before first use and if canister has not been used for more than 3 days; it is not necessary to shake the canister Capsules are for oral inhalation only with the HandiHaler inhalation device and must not be swallowed. Store capsules in blister packaging and remove immediately before use. If capsules are exposed to air, they should be discarded Insert capsule into center of HandiHaler device chamber; hold device with mouthpiece upwards and press the green button once to pierce the capsule. Clean HandiHaler device with warm water once a month and allow to dry for 24 hours Exhale completely then breathe in slowly and Prior to first use, insert cartridge into inhaler unit and actuate inhaler towards ground until aerosol cloud appears, then repeat 3 times to prime unit. If the inhaler is not used for more than 3 days, actuate the device 1 time to prime for use. If it is not used for more than 21 days, repeat the initial priming process
5 PK/PD Absorption: within 15 minutes; not readily absorbed into systemic circulation Peak effect: 1-2 hours Distribution: 15% of dose reaches lower airways Protein binding: 9% Metabolism: partially metabolized to inactive ester hydrolysis products Half-life: 2 hours Excretion: urine (50%) Contraindications Hypersensitivity to atropine or its derivatives Hypersensitivity to ipratropium bromide or any component of the product Warnings Not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response Hypersensitivity reactions, including anaphylaxis: discontinue medication Glaucoma: use with caution in narrow-angle glaucoma Paradoxical bronchospasm: discontinue medication and institute alternative therapy Urinary retention: may deeply at a rate enough to hear or feel the capsule vibrate and hold breath as long as is comfortable. If the inhaler is not used for more than 3 days, actuate the device 1 time to prime for use. If not used more than 21 days, repeat initial priming process Absorption: poorly absorbed from GI tract, systemic absorption may occur from lung Peak effect: 7 minutes Distribution: 32 L/kg Protein binding: 72% Metabolism: hepatic (minimal), via CYP2D6 and CYP3A4 Half-life: ~25 hours Excretion: urine (7% of an inhaled dose) Hypersensitivity to tiotropium, ipratropium, or any component of the product Absorption: 5 to 7 minutes Peak: 1.5 to 3 hours Bioavailability: 33% Distribution: 32 L/kg Protein binding: 72% Metabolism: 25% via CYP2D6 and CYP3A4 oxidation with subsequent glutathione conjugation Half-life: 25 hours Excretion: urine (18.6% of an inhaled dose) Hypersensitivity to tiotropium, ipratropium, or any component of the product Not for acute use or as rescue medication Hypersensitivity reactions, including anaphylaxis: discontinue medication Glaucoma: use with caution in narrow-angle glaucoma Paradoxical bronchospasm: discontinue medication and institute alternative therapy Urinary retention: may worsen symptoms, leading to painful urination or difficulty passing urine
6 Drug-drug interaction Common Side effects worsen symptoms, leading to painful urination or difficulty passing urine Anticholinergics: Avoid coadministration due to additive effects Bronchitis, COPD exacerbation, Dyspnea, and Headache Upper respiratory tract infection, Dry mouth, Sinusitis, Pharyngitis, Nonspecific chest pain, Urinary tract infection, Dyspepsia, and Rhinits Pharyngitis, Cough, Dry mouth, Sinusitis Monitoring Pulmonary function tests, proper inhalation technique Pregnancy Category B. No teratogenic effects seen in animal studies Lactation It is not known if ipratropium is excreted in breast milk. The US labeling recommends that caution be exercised when administering to breastfeeding women. Storage and stability Store at 20-25ºC (68-77ºF), excursion permitted between 15 and 30ºC (59 and 86ºF). Do not puncture the canister or use or store near heat or open flame. Bursting may occur at temperatures above 120 ºF. Discard canister when indicator displays zero How supplied 17 mcg/actuation with 200 actuations per 12.9g canister FEV1, peak flow, other pulmonary function tests, reduction in COPD exacerbation; anticholinergic adverse reactions; signs and symptoms of narrow angle glaucoma and urinary retention Category C. Adverse effects seen in animal studies It is not known if tiotropium is excreted in breast milk. The US labeling recommends that caution be exercised when administering to breast-feeding women Store at 25ºC (77ºF), excursions permitted between 15 and 30ºC (59 and 86ºF). Do not expose capsules to extreme temperature or moisture. Do not store capsules in HandiHaler device Store at 25 C (77 F), excursions are permitted between 15 C and 30 C (59 F and 86 F). Avoid freezing 18 mcg/capsule COPD: 2.5 mcg/actuation Asthma: 1.25mcg/actuation
7 Monotherapy Anticholinergic Bronchodilator Drugs (cont.) MOA Incruse Ellipta (umeclidinium bromide) Long-acting anticholinergic agent that competitively and reversibly inhibits acetylcholine at M3 receptors in bronchial smooth muscle causing bronchodilation Seebri Neohaler (glycopyrrolate) Long-acting anticholinergic agent than competitively and reversibly inhibits acetylcholine at muscarinic subtypes 1 to 3 in bronchial smooth muscle causing bronchodilation Tudorza Pressair (aclidinium) Long-acting anticholinergic agent that competitively and reversibly inhibits acetylcholine at M3 receptors in bronchial smooth muscle causing bronchodilation Usual Dosing 1 inhalation daily 1 capsule inhaled twice daily 1 inhalation twice daily FDA Indication Pediatric Indication COPD Efficacy and safety not established Administration PK/PD When ready for a dose, open the cover of the inhaler; a click will be heard and the counter will decrease to indicate the device is ready. Before inhaling the dose, breath our fully, then place device firmly between lips and inhale with a long, deep, steady breath through the mouth. Do not breathe in through nose or cover air vent on the inhaler. Hold breath for 3 to 4 seconds or for as long as comfortable, and exhale slowly. Opening and closing the device without an inhalation will result in a lost dose Absorption: lung, minimum contribution from oral absorption Time to Peak: 5 to 15 minutes Distribution: 86L Protein binding: 89% Administer by inhalation route using the Neohaler device at the same time every day; do not swallow capsule. Store capsules in the blister pack until immediately before use. Use the new inhaler included with each prescription. Discard any capsules that are exposed to air and not used immediately Absorption: rapid Time to Peak: 5 minutes Bioavailability: ~40% Distribution: 83L Protein binding: 38-41% Metabolism: hepatic (minimal) Half-life: hours Excretion: urine, bile Press and release the green button and then make sure the control window has changed from red to green before inhalation. Breathe out completely before forming a tight seal with lips around the mouthpiece and breathe in; there will be a clicking sound and the control window should turn red after inhalation Time to Peak: 10 minutes Bioavailability: ~6% Distribution: 300L Protein binding: 38-41% Metabolism: rapid and extensive hydrolysis via plasma esterases to inactive alcohol and acid metabolites Half-life: 5-8 hours
8 Contraindications Warnings Drug-drug interaction Common Side effects Monitoring Pregnancy Lactation Metabolism: oxidation followed by conjugation, substrate of CYP2D6 and P-gp Half-life: 11 hours Excretion: urine (<1%) and feces (92%) Severe hypersensitivity to milk proteins Hypersensitivity to any ingredient History of known hypersensitivity to glycopyrrolate or any of the ingredients Do not initiate in acutely deteriorating COPD or to treat acute symptoms Glaucoma: use with caution in narrow-angle glaucoma Paradoxical bronchospasm: discontinue medication and institute alternative therapy Urinary retention: may worsen symptoms, leading to painful urination or difficulty passing urine Anticholinergics: Avoid coadministration due to additive effects Nasopharyngitis, Upper respiratory tract infection, Cough, Arthralgia Upper respiratory tract infection and Nasopharyngitis FEV1, peak flow, other pulmonary function tests; signs and symptoms of narrow angle glaucoma and urinary retention Category C. Adverse events were not observed in animal reproduction studies. It is not known if umeclidinium is excreted into breast milk. The US labeling recommends that caution be exercised Category C It is not known if glycopyrrolate is excreted into breast milk. The US labeling recommends that caution be exercised when administering to breast-feeding women. May suppress lactation. Excretion: urine (0.09%) Severe hypersensitivity to milk proteins Hypersensitivity to any ingredient Not for acute use or as a rescue medication Glaucoma: use with caution in narrow-angle glaucoma Paradoxical bronchospasm: discontinue medication and institute alternative therapy Urinary retention: may worsen symptoms, leading to painful urination or difficulty passing urine Hypersensitivity reactions: angioedema, bronchospasm, or anaphylaxis may occur in patients with severe hypersensitivity to milk proteins Headache, Nasopharyngitis, Cough FEV1, peak flow, other pulmonary function tests; signs and symptoms of narrow angle glaucoma and urinary retention; hypersensitivity reactions in patients with prior hypersensitivity to atropine Category C. Adverse effects were observed in animal reproduction studies. Excretion of aclidinium into human milk is probable as it was observed in animal studies. The US labeling recommends that caution be exercised when administering to breast-feeding women.
9 when administering to breast-feeding women. Storage and stability Store at 20-25ºC (68-77ºF), excursion permitted between 15 and 30ºC (59 and 86ºF). Protect from direct heat, sunlight, and moisture. Discard 6 weeks after opening or when the dose counter reads zero Store capsules in blister pack at 25ºC (77ºF), excursions permitted between 15 and 30ºC (59 and 86ºF) until immediately before use. Protect from moisture. Discard capsule if not used immediately Store under dry conditions, in the sealed ouch, at 25ºC (77ºF), excursions permitted between 15 and 30ºC (59 and 86ºF). Remove pouch immediately prior to use. Discard inhaler 45 days after removal, when the 0 marking with a red background shows in the dose indicator, or when the inhaler locks How supplied 62.5 mcg/actuation 15.6 mcg/capsule 400 mcg/actuation Combination Anticholinergic Bronchodilator Drugs Anoro Ellipta (umeclidinium/ vilanterol) MOA Stiolto Respimat (tiotropium/ olodaterol) Utibron Neohaler (glycopyrrolate/ indacaterol) Combination of a long-acting anticholinergic agent which reversibly inhibits the M3 receptor at the smooth muscle, leading to bronchodilation, and a long-acting beta-2 agonist which stimulates adenyl cyclase resulting in increased intracellular camp which triggers bronchial smooth muscle relaxation Usual Dosing 1 inhalation daily 2 inhalations once daily 1 capsule inhaled twice daily FDA Indication COPD Pediatric Efficacy and safety not established Indication Administration Administer at the For first use or if inhaler same time each day. has not been used for Do not open the more than 21 days, prime cover until ready to the unit by actuating use. Exhale fully inhaler toward the ground before taking one until aerosol cloud is long, steady, deep visible and then repeating breath through the 3 more times. If the unit mouthpiece. Hold has not been used for breath for 3 to 4 more than 3 days, actuate seconds and exhale inhaler once prior to use. slowly and gently Do not cover the air vents when administering the inhaler. Avoid contact with eyes Do not swallow capsules. Use only with Neohaler device. Administer at the same time each day, once in the morning and once in the evening. Store capsules in the blister container and only remove immediately prior to use Combivent Respimat (ipratropium/albuterol) Combination of a short-acting anticholinergic agent which blocks acetylcholine at parasympathetic sites leading to bronchodilation, and a short-acting beta2 agonist which relaxes bronchial smooth muscle 1 inhalation four times daily For first use or if inhaler has not been used for more than 21 days, prime the unit by actuating inhaler toward the ground until aerosol cloud is visible and then repeating 3 more times. If the unit has not been used for more than 3 days, actuate inhaler once prior to use. Do not cover the air vents when administering the inhaler. Avoid
10 PK/PD Contraindicatio ns Warnings Absorption: systemic, primarily via lungs, 5 to 15 minutes Distribution: Umeclidinium: 30,200 L; vilanterol: 1,240 L Protein binding: umeclidinium: 89%; vilanterol: 94% Metabolism: hepatic via CYP2D6 (umeclidinium) and CYP3A4 (vilanterol) Half-life: 11 hours Excretion: Urine (<1% umeclidinium; 70% vilanterol); feces (92% umeclidinium; 30% vilanterol) Severe hypersensitivity to milk proteins Absorption: tiotropium: 5 to 7 minutes; olodaterol: 10 to 20 minutes Distribution: Tiotropium: 32 L/kg; olodaterol: 1,110 L Protein binding: tiotropium: 72%; olodaterol: 60% Bioavailability: tiotropium: 33%; olodaterol: 30% Metabolism: tiotropium 25% via CYP2D6 and CYP3A4; olodaterol: extensively hepatic via CYP2C9 and CYP2C8 Half-life: Tiotropium: 25 hours; olodaterol: 45 hours Excretion: tiotropium: 18.6% in urine; olodaterol: 9% renal as parent and metabolites and 84% in feces Use in the treatment of asthma without a concomitant long-term asthma control medication Hypersensitivity to tiotropium, olodaterol, or any component of the product Absorption: glycopyrrolate: 5 minutes; indacaterol: 15 minutes Distribution: glycopyrrolate: 83 L; indacaterol: L Protein binding: glycopyrrolate: 38-41%; indacaterol: 95% Bioavailability: 43-45% Metabolism: glycopyrrolate: 30-40% of total elimination via multiple CYP enzymes; indacaterol: primary site via UGT1A1 and CYP3A4 Half-life: glycopyrrolate: hours; indacaterol: hours Excretion: glycopyrrolate: 60-70% renal; indacaterol: less than 2% renally, 54% unchanged and 23% as metabolites in feces Use in the treatment of asthma without a concomitant long-term asthma control medication Boxed Warning: Long-acting beta-2 agonists increase the risk of asthma-related deaths. Do not initiate in acutely deteriorating COPD or to treat acute symptoms Cardiovascular: Increased risk for cardiovascular effects and ECG changes Diabetes: may increase serum glucose and aggravate preexisting DM and ketoacidosis Glaucoma: use with caution in narrow-angle glaucoma Hypokalemia: may decrease serum potassium Paradoxical bronchospasm: discontinue medication and institute alternative therapy Urinary retention: may worsen symptoms, leading to painful urination or contact with eyes Absorption: ipratropium: not readily absorbed into systemic circulation from lungs; albuterol: rapid Distribution: ipratropium: 15% of dose reaches lower airways Protein binding: ipratropium: 9%; albuterol: 10% Metabolism: ipratropium: partial metabolism through liver; albuterol: hepatically to an inactive sulfate Half-life: ipratropium: 2 hours; albuterol: ~4 hours Excretion: ipratropium: 50% urine; albuterol: 30% as unchanged drug in the urine and <20% in feces Hypersensitivity to atropine or any of its derivatives. Hypersensitivity to ipratropium, albuterol, or any component of the product Paradoxical bronchospasm: Discontinue immediately and treat with alternative therapy Cardiovascular: use with caution due to beta-adrenergic stimulation Ocular effects:
11 Drug-drug interaction Common Side effects difficulty passing urine. Renal impairment: monitor closely for anticholinergic adverse events Seizure disorders: Use with caution as this drug may result in CNS stimulation Thyrotoxicosis: this may be exacerbated Strong CYP3A4 inhibitors: use with caution due to cardiovascular effects MAOIs and TCAs: use with extreme caution due to cardiovascular effects Beta-blockers: use with caution due to potential for bronchospasm and decreased effectiveness Diuretics: use with caution due to ECG changes and/or hypokalemia Anticholinergics: Avoid coadministration due to additive effects Pharyngitis Sinusitis Lower respiratory tract infection Other adrenergic drugs: use with caution Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics: us with caution due to ECG changes and hypokalemia MAOIs, TCAs, and drugs that prolong QTc interval: use with extreme caution Beta-blockers: use with caution due to potential for bronchospasm and decreased effectiveness Anticholinergics: Avoid coadministration due to additive effects Nasopharyngitis Back Pain Cough Other adrenergic drugs: use with caution Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics: us with caution due to ECG changes and hypokalemia MAOIs, TCAs, and drugs that prolong QTc interval: use with extreme caution Beta-blockers: use with caution due to potential for bronchospasm and decreased effectiveness Anticholinergics: Avoid coadministration due to additive effects Nasopharyngitis Hypertension Avoid spraying into eyes and monitor patients with narrow-angle glaucoma Urinary retention: use with caution Anaphylaxis: Discontinue if hypersensitivity reactions seen such as urticaria, angioedema, rash, bronchospasm, or orpharyngeal edema. Use with caution in patients with convulsive disorders, hypothyroidism, or diabetes mellitus Anticholinergics: Avoid coadministration due to additive effects Beta-adrenergic agonists: Avoid coadministration due to cardiovascular effects Beta-blockers: Consider alternative therapy due its inhibition of albuterol Diuretics: Consider monitoring potassium levels due to ECG changes and/or hypokalemia MAOIs or TCAs: Consider alternative therapy Upper respiratory infection Nasopharyin gitis
12 Monitoring Pregnancy Lactation Storage and stability Constipation Diarrhea Pain in extremity Muscle spasms Neck pain Chest pain FEV1, peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; ocular changes FEV1, peak flow, and/or other pulmonary function tests; anticholinergic effects; glaucoma, and urinary retention, increased use of SABAs FEV1, FVC, and/or other pulmonary function tests; serum potassium, serum glucose; blood pressure, heart rate; CNS stimulation; increased use of SABAs Cough Bronchitis Headache Dyspnea FEV1, FVC, peak flow, and/or other pulmonary function tests; shortness of breath; serum potassium; blood pressure, heart rate Category C. Beta-agonists have the potential to affect uterine contractility if administered during labor It is not known if It is not known if It is not known if It is not known if umeclidnium or tiotropium or olodaterol is glycopyrrolate or ipratropium or albuterol vilanterol is excreted excreted in breast milk. indacaterol is excreted are excreted in breast milk. in breast milk. The The US labeling in breast milk. The US The US labeling US labeling recommends that caution labeling recommends recommends that caution recommends that be exercised when that caution be be exercised when caution be exercised administering to breastfeeding exercised when administering to breast- when administering women. administering to breastfeeding women. to breast-feeding feeding women. women. Store at 20-25ºC (68-77ºF), excursion permitted between 15 and 30ºC (59 and 86ºF). Protect from moisture, direct heat, or sunlight. Discard inhaler after 6 weeks after initially opening the foil tray or when all the blisters have been used, whichever comes first How supplied umeclidinium 62.5 mcg/vilanterol 25 mcg Store at 25ºC (77ºF), excursions permitted between 15 and 30ºC (59 and 86ºF). Protect from freezing. Discard 3 months after first use or when locking mechanism is engages, whichever comes first tiotropium 2.5 mcg/ olodaterol 2.5 mcg Store at 25ºC (77ºF), excursions permitted between 15 and 30ºC (59 and 86ºF). Store capsules in original blister to protect from light and moisture glycopyrrolate 15.6 mcg/indacaterol 27.5mcg Store at 25ºC (77ºF), excursions permitted between 15 and 30ºC (59 and 86ºF). Avoid freezing. Discard when locking mechanism is engaged or 3 months after first use, whichever comes first ipratropium 20mcg/albuterol 100 mcg
13 References: 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Vancouver (WA): Global Initiative for Chronic Obstructive Lung Disease (GOLD); Tudorza Pressair [package insert]. St. Louis, MO: Almirall; July Spiriva Handihaler [package insert]. Boehringer Ingelheim, October Anoro Ellipta [package insert]. Research Triangle Park, NC: GSK; December Fuhr R, Magnussen H, Sarem K, et al. Efficacy of aclidinium bromide 400 mcg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest. 2012;141(3): Chapman K, Beeh K, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulmonary Medicine 2014, 14:4. Change Control Date Change 05/17/2017 Added Stiolto Respimat to Medi-Cal formulary Revised criteria for non-formulary COPD long acting muscarinic agonist inhaler: o Failure or clinically significant adverse effects to ONE formulary long acting bronchodilator. Revised criteria for Non-formulary COPD long acting combination muscarinic agonist and beta agonist inhaler o Failure or clinically significant adverse effects to Stiolto Respimat
Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationMEDICATION GUIDE ANORO ELLIPTA
MEDICATION GUIDE ANORO ELLIPTA [a-nor oh e-lip-ta] (umeclidinium and vilanterol inhalation powder) for oral inhalation What is the most important information I should know about ANORO ELLIPTA? ANORO ELLIPTA
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationPATIENT INFORMATION INCRUSE ELLIPTA
PATIENT INFORMATION INCRUSE ELLIPTA [IN-cruise e-lip-ta] (umeclidinium inhalation powder) for oral inhalation What is INCRUSE ELLIPTA? INCRUSE ELLIPTA is an anticholinergic medicine. Anticholinergic medicines
More informationAnoro Ellipta Patient Handout
Anoro Ellipta Patient Handout 1. OPEN Slide the cover down to expose the mouthpiece. You should hear a click. The counter will count down by 1 number. Do not shake this kind of inhaler. Note: If you open
More informationIMPORTANT: PLEASE READ
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr Spiriva Respimat Tiotropium Bromide Monohydrate Inhalation Solution Read this carefully before you start taking SPIRIVA RESPIMAT and each time you
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator
Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules
More informationhydrochloride) from the mouthpiece. PART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr Inspiolto Respimat Tiotropium (as Tiotropium Bromide Monohydrate) / Olodaterol (as Olodaterol Hydrochloride) Inhalation Solution Read this carefully before you start taking
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationChronic obstructive pulmonary disease (COPD) is a progressive,
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Improving Lung Function (FEV 1 ) in COPD Through Appropriate Counseling on Use of Inhaled Medications
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationChapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 7 Anticholinergic (Parasympatholytic) Bronchodilators Clinical Indications for Use Indication for anticholinergic bronchodilator COPD maintenance Indication for combined anticholinergic and β-agonist
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationPATIENT INFORMATION BREO ELLIPTA
PATIENT INFORMATION BREO ELLIPTA [BRE-oh e-lip-ta] (fluticasone furoate and vilanterol inhalation powder) for oral inhalation What is BREO ELLIPTA? BREO ELLIPTA combines an inhaled corticosteroid (ICS)
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationA Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD
A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD Chris Federico PharmD, BCACP RIPF Kimberly McDonough Spring Seminar May 4, 2016 Disclosure I have no actual
More informationPatient Information ARNUITY ELLIPTA (ar-new-i-te e-lip-ta) (fluticasone furoate inhalation powder) for oral inhalation use What is ARNUITY ELLIPTA?
Patient Information ARNUITY ELLIPTA (ar-new-i-te e-lip-ta) (fluticasone furoate inhalation powder) for oral inhalation use What is ARNUITY ELLIPTA? ARNUITY ELLIPTA is an inhaled corticosteroid (ICS) medicine
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationDrug Monograph. Brand Name: Arcapta Neohaler. Generic Name: Indacaterol. Manufacturer¹,²: Novartis
Drug Monograph Brand Name: Arcapta Neohaler Generic Name: Indacaterol Manufacturer¹,²: Novartis Drug Class¹,²,³, : Beta2-Adrenergic Agonist, Long-Acting Uses: Labeled Uses¹,²,³, : Used for long-term maintenance
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationMDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
More informationTiotropium Bromide/Olodaterol (Stiolto Respimat) Once-Daily Combination Therapy for the Maintenance of COPD
DrUG FOrECAST Tiotropium Bromide/Olodaterol (Stiolto Respimat) Once-Daily Combination Therapy for the Maintenance of COPD Juan F. Mosley II, PharmD, CPh, AAHIVP; Lillian L. Smith, PharmD, CPh, MBA; and
More informationAtrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
ATTENTION PHARMACIST: Detach "Patient's Instructions for Use" from package insert and dispense with the product. Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol For Oral Inhalation Only Rx only
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.69 Effective Date: 11/15 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationBREEZHALER. Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate)
Medications available: Onbrez (indacaterol maleate) Seebri (glycopyrronium bromide) Ultibro (glycopyrronium bromide/ (indacaterol maleate) BREEZHALER Please date initial after you have directly observed
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE
More informationMEDICATION GUIDE. ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol
MEDICATION GUIDE ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg) Inhalation
More informationIPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationComposition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).
VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationPage 1 of 23. Reference ID:
1 HIGHLIGHTS OF PRESCRIBING INFORMATION 38 Paradoxical bronchospasm: Discontinue TUDORZA 2 39 PRESSAIR and consider other treatments if 3 These highlights do not include all the 40 paradoxical bronchospasm
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationHow to use your QVAR RediHaler (beclomethasone dipropionate)
(beclomethasone dipropionate) 40 mcg, 80 mcg What is my prescription? Special instructions Take every day to control your symptoms. Rinse mouth thoroughly with water and spit after each use. What can I
More informationHistory & Development
RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationINCRUSE ELLIPTA PRODUCT INFORMATION
INCRUSE ELLIPTA PRODUCT INFORMATION NAME OF THE MEDICINE Umeclidinium (as bromide) Structure of umeclidinium bromide: OH N O Br Chemical Name: The chemical name of umeclidinium bromide is 1- Azoniabicyclo[2.2.2]octane,
More informationAppendix M: Device Technique
Nursing Care of Dyspnea: The 6th Vital Sign in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Appendix M: Device Technique Medications: Inhalation Devices Medications come in many forms.
More informationUTIBRON NEOHALER (indacaterol and glycopyrrolate) Inhalation Powder for your COPD symptoms
UTIBRON NEOHALER (indacaterol and glycopyrrolate) Inhalation Powder for your COPD symptoms INDICATION UTIBRON NEOHALER (indacaterol and glycopyrrolate) is a combination of a long-acting beta2-adrenergic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationSTRIVERDI RESPIMAT (olodaterol) Inhalation Spray FOR ORAL INHALATION Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STRIVERDI RESPIMAT safely and effectively. See full prescribing information for STRIVERDI RESPIMAT.
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STRIVERDI RESPIMAT safely and effectively. See full prescribing information for STRIVERDI RESPIMAT.
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationPATIENT INFORMATION. ADVAIR DISKUS [AD vair DISK us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation
PATIENT INFORMATION ADVAIR DISKUS [AD vair DISK us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is ADVAIR DISKUS? ADVAIR DISKUS combines the inhaled corticosteroid
More informationIndacaterol. Powder capsule administered by a Breezhaler (Onbrez ) or Neohaler (Acapta ) Mechanism of Action Ultra Long-acting beta-2 agonist (LABA)
Indacaterol Powder capsule administered by a Breezhaler (Onbrez ) or Neohaler (Acapta ) Mechanism of Action Ultra Long-acting beta-2 agonist (LABA) Clinical Application Indications: The long-term maintenance
More informationIncruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD):
Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): An introduction for Clinical Commisioning Groups and Health
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationDULERA [dew-lair-ah] 100 mcg/5 mcg DULERA 200 mcg/5 mcg What is DULERA? DULERA is not used to relieve sudden breathing problems Do not use DULERA:
PATIENT INFORMATION DULERA [dew-lair-ah] 100 mcg/5 mcg (mometasone furoate 100 mcg and formoterol fumarate dihydrate 5 mcg) Inhalation Aerosol DULERA 200 mcg/5 mcg (mometasone furoate 200 mcg and formoterol
More informationTIOVA Inhaler (Tiotropium bromide)
Published on: 18 Sep 2014 TIOVA Inhaler (Tiotropium bromide) Composition TIOVA Inhaler Each actuation delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium... 9 mcg Suspended in propellant
More informationSPIRIVA RESPIMAT (tiotropium bromide) inhalation spray, for oral inhalation Initial U.S. Approval: 2004
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA RESPIMAT safely and effectively. See full prescribing information for SPIRIVA RESPIMAT. SPIRIVA
More informationBreezhaler. Open to see clear capsule. How do I use my Breezhaler? Care of my Breezhaler
Breezhaler 3 Pull cap off Press buttons once and release Breathe in rapidly and steadily. Hold. Open. Place capsule in chamber. Close (click). Breathe out 4 Open to see clear capsule. If not all clear
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationPocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals
Pocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals Endorsed by NHSGGC Respiratory Managed Clinical Network; June 2016 Designed by Medical Illustration Services Contents
More information*Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SEEBRI NEOHALER safely and effectively. See full prescribing information for SEEBRI NEOHALER. SEEBRI
More informationTRELEGY ELLIPTA Fluticasone furoate/umeclidinium/vilanterol dry powder for oral inhalation
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION TRELEGY ELLIPTA Fluticasone furoate/umeclidinium/vilanterol dry powder for oral inhalation Read this leaflet carefully
More informationAtrovent Administration
Atrovent Administration ICEMA Training 2007 Sherri Shimshy RN OBJECTIVES Describe the pharmacology of Atrovent Identify the indications for use of Atrovent in the Adult Population Identify the indications
More informationIncorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
More informationONBREZ BREEZHALER should only be used to treat COPD.
CONSUMER INFORMATION Pr ONBREZ BREEZHALER Indacaterol maleate This leaflet is part III of a three-part "Product Monograph" published when ONBREZ BREEZHALER was approved for sale in Canada and is designed
More informationPRODUCT MONOGRAPH. Tiotropium (as tiotropium bromide monohydrate) and Olodaterol (as olodaterol hydrochloride) Inhalation Solution
PRODUCT MONOGRAPH Pr INSPIOLTO RESPIMAT Tiotropium (as tiotropium bromide monohydrate) and Olodaterol (as olodaterol hydrochloride) Inhalation Solution 2.5 mcg/2.5 mcg per actuation INSPIOLTO RESPIMAT
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationSUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006
SUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006 1. NAME OF THE MEDICINAL PRODUCT FAVINT 18 microgram, inhalation powder, hard capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains
More informationNew Drug Update April 2016
New Drug Update 2015-16 April 2016 C. Wayne Weart, Pharm D, FASHP, FAPhA, BCPS Professor of Clinical Pharmacy and Outcome Sciences South Carolina College of Pharmacy Professor of Family Medicine Medical
More informationSpiriva Respimat. What is in this leaflet. Before you use Spiriva Respimat. What Spiriva Respimat is used for
Spiriva Respimat Solution for Inhalation Tiotropium Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Spiriva Respimat. It does not contain all
More informationANORO TM ELLIPTA TM 55/22 mcg Inhalation Powder
ANORO TM ELLIPTA TM 55/22 mcg Inhalation Powder WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled
More informationULTIBRO BREEZHALER should only be used to treat COPD. ULTIBRO BREEZHALER should not be used to treat asthma.
PART III: CONSUMER INFORMATION Pr ULTIBRO BREEZHALER Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules Read this carefully before you start taking ULTIBRO BREEZHALER
More informationANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation Initial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ANORO ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA
More informationSEROBID Inhaler (Salmeterol xinafoate)
Published on: 10 Jul 2014 SEROBID Inhaler (Salmeterol xinafoate) Composition Each actuation delivers: Salmeterol (as Salmeterol Xinafoate IP) 25 mcg Suspended in propellant HFA 134a.....q.s. Dosage Form
More informationSPIRIVA HANDIHALER (tiotropium bromide inhalation powder), for oral inhalation use Initial U.S. Approval: 2004
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA HANDIHALER safely and effectively. See full prescribing information for SPIRIVA HANDIHALER.
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION ARNUITY ELLIPTA fluticasone furoate dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published when ARNUITY ELLIPTA was approved
More informationHow can I benefit most from my COPD medications?
Fact Sheet: COPD Medications and Delivery Devices How can I benefit most from my COPD medications? COPD medications can improve your symptoms. By taking the right medication at the right time, you can
More informationSTIOLTO RESPIMAT (tiotropium bromide and olodaterol) inhalation spray, for oral inhalation use Initial U.S. Approval: 2015
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STIOLTO RESPIMAT safely and effectively. See full prescribing information for STIOLTO RESPIMAT. STIOLTO
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More informationDate of Birth: Phone: ( ) Gender: M F. City: State: Zip:
To apply for help in affording your Utibron Neohaler (indacaterol and glycopyrrolate) Inhalation Powder prescription, please mail completed application to: Sunovion Support Prescription Assistance Program
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More information